The Mother & Baby Substance Exposure Initiative, part of the Medication Assisted Treatment Expansion Project, is a hospital and community-based effort to improve outcomes for mothers and newborns impacted by substance exposure, with a specific focus on Opioid Use Disorder. The Mother & Baby Substance Exposure Initiative emphasizes care that maintains the mother/baby dyad throughout the hospital stay and will also address treatment and prevention of substance exposure during and after pregnancy.
CPQCC and CMQCC are jointly implementing this project in collaboration with Health Management Associates (HMA). The Mother & Baby Substance Exposure Initiative is funded by the California Department of Health Care Services (DHCS) as part of a Substance Abuse and Mental Health Services Administration (SAMHSA) State Opioid Response grant.
Key components of this initiative include:
- Leading a multidisciplinary taskforce of experts from across California to develop a toolkit for maternal and newborn care providers on perinatal substance exposure, with a focus on opioid exposure
- Implementing quality improvement collaboratives for hospitals in selected counties across Northern, Central and Southern California
- Collecting and reporting data to support quality improvement
- Mobilizing and supporting public and private partners across the state
- Networking and learning from other states that have implemented the Alliance for Innovation on Maternal Health (AIM) National Collaborative Opioid Bundle
The Mother & Baby Substance Exposure Initiative Toolkit was developed by a multidisciplinary taskforce of maternal and newborn health care experts to improve outcomes for substance-exposed mothers and newborns.
The interactive online toolkit shares best practices across the care continuum for:
- Screening Assessment and Level of Care Determination
- Transition of Care
Best practices are organized both by topic area and the type of practice setting: outpatient, labor and delivery and nursery-NICU. Key themes of the toolkit include:
- Every pregnant woman should be screened
- Every pregnant woman with opioid use disorder (OUD) should be on Medication Assisted Treatment (MAT)
- Providers should encourage non-pharmacologic treatment for neonatal abstinence syndrome (NAS) where appropriate based on increasing evidence demonstrating its superiority
- Moms and babies should receive support to keep them together